WebMay 12, 2024 · The purpose of this study was to evaluate prediction of prognosis after first-line radioimmunotherapy (RIT) of advanced follicular non-Hodgkin lymphoma (FL), by imaging with fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography (18F-FDG-PET/CT) three months after induction treatment by Iodine-131 … WebFeb 27, 2008 · 1.1 Rituximab, within its marketing authorisation, in combination with chemotherapy, is recommended as an option for the induction of remission in people with …
Clinicopathological characteristics, local treatment, and …
WebMaintenance Rituximab Maintenance 27 21 13 68 S0806 NHL, Adv, R-CHOP + SAHA R-CHOP+SAHA (400mg D1 -9) 4 7 0 11 R-CHOP ... current follicular lymphoma with grade I or II disease by REAL classification or grade 1, 2 or … WebOct 16, 2024 · Conversely, the absence of OS prolongation by rituximab maintenance was not unexpected, since statistical modeling have indicated for years that the association between PFS and OS tends to be weaker for malignancies with a long survival after progression, such as follicular lymphoma, which explains how the PFS advantage … humberto ak’abal poemas
Rituximab Maintenance in Follicular Lymphoma – Hematology
http://lw.hmpgloballearningnetwork.com/site/onc/conference-coverage/rituximab-monotherapy-prolongs-time-next-treatment-low-tumor-burden WebAug 25, 2014 · Rituximab is often used as part of induction therapy for follicular lymphoma and, for patients who have responded to induction therapy, can be used as maintenance … WebDec 12, 2024 · After a median follow-up of 12.3 years, rituximab is highly effective at delaying time to next treatment in patients with low tumor burden follicular lymphoma. Long-term findings from the phase 3 Watch & Wait trial show that after a median follow-up of 12.3 years, rituximab is highly effective at delaying time to next treatment in patients … humberto araujo zelada